Leuko Revenue and Competitors

Boston, MA USA

Location

#7833

Growjo Ranking

Estimated Revenue & Valuation

  • Leuko's estimated annual revenue is currently $4.5M per year.(i)
  • Leuko's estimated revenue per employee is $251,000

Employee Data

  • Leuko has 18 Employees.(i)
  • Leuko grew their employee count by 6% last year.

Leuko's People

NameTitleEmail/Phone
1
Cofounder & CTOReveal Email/Phone
2
Co-Founder and CEOReveal Email/Phone
3
Cofounder & CTOReveal Email/Phone
4
Co-Founder and CEOReveal Email/Phone
5
Chief Data ScientistReveal Email/Phone
6
Chief Medical OfficerReveal Email/Phone
7
Chief Medical OfficerReveal Email/Phone
8
Hardware EngineerReveal Email/Phone
9
Product Software EngineerReveal Email/Phone
10
Deep Learning EngineeringReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.8M393%N/AN/A
#2
$8.5M343%N/AN/A
#3
$3M12-29%N/AN/A
#4
$5630M7477-11%$450MN/A
#5
$4.5M186%N/AN/A
#6
$7.2M5727%$29.6MN/A
#7
$14.3M57-12%N/AN/A
#8
$2.3M186%$44MN/A
#9
$40.7M162-1%N/AN/A
#10
$45.7M182-5%N/AN/A
Add Company

What Is Leuko?

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$4.5M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Leuko News

2022-04-20 - Judges: Joint winners at INVEST Pitch Perfect's RPM track ...

Another company Leuko, based in Spain, is targeting cancer patients with a device that claims to be the first device for non-invasive white...

2022-04-20 - Judges: Joint winners at INVEST Pitch Perfect's RPM track ...

Another company Leuko, based in Spain, is targeting cancer patients with a device that claims to be the first device for non-invasive white...

2022-03-22 - Trastuzumab deruxtecan shows 'terrific activity' in second line ...

... GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics,...

2022-03-22 - Trastuzumab deruxtecan shows 'terrific activity' in second line ...

... GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.1M18-22%$13M
#2
$1.5M18-36%N/A
#3
$0.5M18-5%$9.5M
#4
$2.2M18-5%N/A
#5
$0.6M180%$4.7M